July 29, 2017 9:27 AM ET

Life Sciences Tools and Services

Company Overview of Personalis, Inc.

Company Overview

Personalis, Inc., a precision medicine company, offers next–generation sequencing-based clinical diagnostic and research services for cancer and inherited genetic diseases. The company provides researchers and clinicians DNA sequencing and interpretation of human exomes and genomes. It also offers ACE Platform, a sequencing and analysis solution to address research and diagnostic questions; ACE ImmunoID, a solution to obtain genomic and transcriptomic data for neoantigen identification; Athena Diagnostics, a diagnostic test for neurological disease cases; and DNA Analysis pipeline for cancer performs alignment and variant calling for germline and somatic variants. In addition, the company pr...

1330 O’Brien Drive

Menlo Park, CA 94025

United States

Founded in 2011





Key Executives for Personalis, Inc.

Co-Founder, Chief Executive Officer and Director
Co-Founder and Member of Clinical & Scientific Advisory Board
Co-Founder and Member of Clinical & Scientific Advisory Board
Co-Founder and Member of Clinical & Scientific Advisory Board
Co-Founder and Member of Clinical & Scientific Advisory Board
Compensation as of Fiscal Year 2017.

Personalis, Inc. Key Developments

Personalis, Inc. Receives Approval from the New York State Department of Health for Clinical Tests Based on the ACE Exome

Personalis, Inc. announced that it has received approvals from the New York State Department of Health for two next-generation sequencing clinical tests based on the Personalis ACE Exome for Inherited Disorders. The Personalis Clinical Laboratory Permit has been granted in the category of Genetic Testing, Molecular. The ACE Exome, based on Personalis’ proprietary ACE (accuracy and content enhanced) technology, covers all ~20,000 RefSeq genes and augments coverage of more than 8,000 biomedically relevant genes, for substantially more uniform sequencing coverage than other commercially available exomes. These molecular tests can now be offered to physicians and patients in New York State. Gaining approval from New York State is in line with Personalis’ overall regulatory strategy for its family of products based on the ACE Exome. The New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP), regulates and oversees clinical diagnostic laboratories that test specimens from New York State residents; including Laboratory Developed Tests (LDTs). The CLEP seeks to ensure the accuracy and reliability of test results in clinical laboratories located in or accepting specimens from New York State (NYS) residents.

Argos Therapeutics Inc. Enters into Strategic Research Agreement with Personalis, Inc

Argos Therapeutics Inc. announced that it has entered into a strategic research agreement with Personalis, Inc. Personalis will serve as the primary genomic analysis service provider to support ongoing research efforts to demonstrate that Argos’ lead product candidate, rocapuldencel-T, specifically targets patient-specific neoantigens without the need to identify them first. Argos will utilize the Personalis ACE ImmunoID™ next-generation sequencing (NGS) platform to evaluate tumor samples collected during clinical development of Argos’ tumor-specific dendritic cell technology to treat renal cell carcinoma. The analytically validated ACE ImmunoID platform offers the unmatched accuracy through whole exome and transcriptome sequencing for tumor/normal evaluation coupled with leading edge bioinformatics and sample tracking to ensure timely delivery of results including neoantigen identification and tumor mutational burden.

Personalis Launches Report Providing In-Depth Characterization of Tumor Neoantigen Peptides

Personalis, Inc. announced it is expanding its services for clinical trials and research by launching its Neoantigen Discovery Report for its ACE ImmunoID service. The ACE ImmunoID service continues to provide best in class, validated exome and transcriptome sequencing with patented ACE technology and calling of expressed somatic variants through combined DNA and RNA analysis. The ACE ImmunoID service has now been extended to include a Neoantigen Discovery Report which predicts peptides which can be generated from each expressed somatic variant and then characterizes those. This characterization includes prediction of MHC Class I & II binding affinities based on the patient’s HLA alleles, and similarity to both self and known antigens. The Neoantigen Discovery Report for ACE ImmunoID provides researchers with a seamless approach to identifying and characterizing potentially immunogenic peptides unique to an individual patient’s cancer. Using the comprehensive characterization of this new report, customers can then prioritize peptides for the development of personalized vaccine therapies. The elements of antigenic potential, projected by this new report, may also assist customers working to understand clinical responses to checkpoint inhibitors, modulators, CAR-T and other immuno-therapies. By combining best-in-class and proprietary tools, Personalis’ Neoantigen Discovery Report aides in the rapid evaluation and prioritization of samples and peptides based on the client’s needs.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Private Placement
June 29, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Personalis, Inc., please visit www.personalis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.